摘要
流感是一种由流感病毒引起的急性呼吸道传染病。抗病毒药物可以缩短病程和减少严重并发症的发生。ZSP1273是一种甲型流感病毒RNA依赖RNA聚合酶(RdRp)聚合酶碱性亚基2(PB2)抑制剂类小分子抗流感病毒药物。Ⅲ期临床试验结果表明,ZSP1273较安慰剂可显著缩短流感症状缓解时间和发热缓解时间,较安慰剂或奥司他韦更快、更有效地降低甲型流感病毒载量,显著缩短病毒转阴时间,并且表现出良好的安全性和耐受性。本文就ZSP1273的基本信息、作用机制、药动学、临床前研究及临床研究等进行概述。
Influenza is an acute respiratory infection caused by influenza virus.Antiviral drugs can shorten the duration of the disease and reduce the occurrence of serious complications.ZSP1273 is a small molecule anti-influenza drug of RNA-de⁃pendent RNA polymerase(RdRp)polymerase basic 2(PB2)subunit inhibitor of influenza A virus.PhaseⅢclinical trial re⁃sults indicate that ZSP1273 significantly shortens the time for influenza symptom remission and fever resolution compared with placebo.Compared with placebo or oseltamivir,ZSP1273 reduces influenza A viral load faster and more effectively,signifi⁃cantly shortens the time for viral transition to negative,and shows good safety and tolerability.This article provides an over⁃view of the basic information,mechanism of action,pharmacokinetics,preclinical research and clinical studies of ZSP1273.
作者
董欣盈
李飞
李行舟
何宇鹏
于芳
DONG Xin-ying;LI Fei;LI Xing-zhou;HE Yu-peng;YU Fang(College of Petrochemical Engineering,Liaoning Petrochemical University,Liaoning Fushun 113001,China;Institute of Pharmacology&Toxicology of the Academy of Military Medical Sciences,National Engineering and Technology Center of Emergency Prevention and Control Drugs,Beijing 100850,China;School of Pharmaceutical Engineering and Biotechnology,Zhejiang Pharmaceutical University,Zhejiang Ningbo 315500,China)
出处
《临床药物治疗杂志》
2024年第1期17-21,共5页
Clinical Medication Journal
